The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal antibody in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.

Jermaine  Coward

Research Funding - AstraZeneca (Inst)

Afaf  Abed

No Relationships to Disclose

Adnan  Nagrial

Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Roche

Research Funding - Akeso Biopharma (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst)

Ben  Markman

Consulting or Advisory Role - Amgen; Amgen

Travel, Accommodations, Expenses - Akeso Biopharma